Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments (2019 - 2025)

Allogene Therapeutics' Change in Acquisitions & Divestments history spans 7 years, with the latest figure at -$110.3 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 200.45% year-over-year to -$110.3 million; the TTM value through Sep 2025 reached -$324.9 million, down 135.22%, while the annual FY2024 figure was $5.4 million, 99.1% down from the prior year.
  • Change in Acquisitions & Divestments for Q3 2025 was -$110.3 million at Allogene Therapeutics, down from $53.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $592.2 million in Q4 2023 and bottomed at -$645.9 million in Q4 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $103.3 million (2024), against an average of $31.7 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 327.43% in 2023 against a maximum downside of 211.64% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at -$645.9 million in 2021, then skyrocketed by 59.68% to -$260.4 million in 2022, then skyrocketed by 327.43% to $592.2 million in 2023, then plummeted by 154.86% to -$324.9 million in 2024, then skyrocketed by 66.05% to -$110.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Change in Acquisitions & Divestments are -$110.3 million (Q3 2025), $53.8 million (Q2 2025), and $56.5 million (Q1 2025).